These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27849649)

  • 1. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
    Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
    Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
    Larsen FO; Markussen A; Diness LV; Nielsen D
    Oncology; 2018; 94(1):19-24. PubMed ID: 28930749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
    Riechelmann RP; Townsley CA; Chin SN; Pond GR; Knox JJ
    Cancer; 2007 Sep; 110(6):1307-12. PubMed ID: 17628484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Iyer RV; Gibbs J; Kuvshinoff B; Fakih M; Kepner J; Soehnlein N; Lawrence D; Javle MM
    Ann Surg Oncol; 2007 Nov; 14(11):3202-9. PubMed ID: 17705089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
    Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
    Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.
    Ramaswamy A; Bhargava P; Srinivas S; Kapoor A; Mishra BK; Gupta A; Mandavkar S; Kannan S; Chaugule D; Patil R; Parulekar M; Nashikkar C; Ankathi SK; Kaushal RK; Naughane D; Daddi A; Mer N; Shetty N; Ostwal V
    J Clin Oncol; 2024 Sep; 42(27):3218-3227. PubMed ID: 39102628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
    Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
    Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
    Koeberle D; Saletti P; Borner M; Gerber D; Dietrich D; Caspar CB; Mingrone W; Beretta K; Strasser F; Ruhstaller T; Mora O; Herrmann R;
    J Clin Oncol; 2008 Aug; 26(22):3702-8. PubMed ID: 18669455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
    Goyal L; Sirard C; Schrag M; Kagey MH; Eads JR; Stein S; El-Khoueiry AB; Manji GA; Abrams TA; Khorana AA; Miksad R; Mahalingam D; Zhu AX; Duda DG
    Clin Cancer Res; 2020 Dec; 26(23):6158-6167. PubMed ID: 32878766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.